Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2000

01-06-2000 | ORIGINAL ARTICLE

Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis

Authors: Merry L. Tetef, Kim A. Margolin, James H. Doroshow, Steven Akman, Lucille A. Leong, Robert J. Morgan Jr., James W. Raschko, Neil Slatkin, George Somlo, Jeffrey A. Longmate, Mary I. Carroll, Edward M. Newman

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2000

Login to get access
Metadata
Title
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis
Authors
Merry L. Tetef
Kim A. Margolin
James H. Doroshow
Steven Akman
Lucille A. Leong
Robert J. Morgan Jr.
James W. Raschko
Neil Slatkin
George Somlo
Jeffrey A. Longmate
Mary I. Carroll
Edward M. Newman
Publication date
01-06-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800000118

Other articles of this Issue 1/2000

Cancer Chemotherapy and Pharmacology 1/2000 Go to the issue

ORIGINAL ARTICLE

Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women

ORIGINAL ARTICLE

Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer

ORIGINAL ARTICLE

A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism

ORIGINAL ARTICLE

Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID) – a phase II study

ORIGINAL ARTICLE

Pharmacokinetics of 2-chloro-2′-deoxyadenosine administered subcutaneously or by continuous intravenous infusion

ORIGINAL ARTICLE

Maximum tolerated doses of methotrexate and 7-hydroxy-methotrexate in a model of acute toxicity in rats
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits